Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
about
Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvementTherapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinomaUnderstanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitorsCharacterizing fatigue associated with sunitinib and its impact on health-related quality of life in patients with metastatic renal cell carcinomaChallenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer.Experience with sunitinib in the treatment of metastatic renal cell carcinomaDuration of targeted therapy for metastatic renal cell carcinoma: a review of current practices.Recent advances in the treatment of advanced renal cell carcinoma: towards multidisciplinary personalized care.Targeted therapy with kinase inhibitors in aggressive endocrine tumors.Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience.Colony, hanging drop, and methylcellulose three dimensional hypoxic growth optimization of renal cell carcinoma cell lines.Efficacy of a protocol including heparin ointment for treatment of multikinase inhibitor-induced hand-foot skin reactions.Sunitinib-induced severe hypoglycemia in a diabetic patient.The use of sunitinib in renal cell carcinoma: where are we now?Management of Adverse Events Associated with Cabozantinib Therapy in Renal Cell Carcinoma.[Side effect management of tyrosine kinase inhibitors in urology : Fatigue and hypothyroidism].The effect of information on preferences for treatments of metastatic renal cell carcinoma.[Side effect management of tyrosine kinase inhibitors in urology : Gastrointestinal side effects].Dose escalation can maximize therapeutic potential of sunitinib in patients with metastatic renal cell carcinoma.
P2860
Q26801279-D59FA4E0-76EB-4266-8EB4-DB38388C7400Q27013665-7EE1ABED-99E9-494A-94F7-6EAC53F4E133Q33698419-4D09EE72-1B6B-4F5B-8F68-73404449C0AAQ34507381-8584CD06-3EE4-4E49-8743-9A6FD6A74031Q35295368-7CF41CAA-2010-417E-84D8-3105EA1F1809Q36231729-79ECE560-6031-4D54-A736-7486092D63F3Q37996240-F5FB68DE-D18C-430F-B2C0-00C48D403182Q38012779-BDA9C17F-FC03-4155-9E76-E8180235CE29Q38107011-7D3387F5-41CA-48FC-B75B-412A276AB960Q38975599-4116795F-91FC-4BC5-9F5C-E1DB9221B359Q40283731-F65A86D0-0280-43D2-95D8-67515B83C9FDQ43785033-26932FC1-4A0A-4E0B-B80A-AB97070319E9Q45063367-0907E1AF-E48B-4B57-8D3C-27CEAD595226Q48634468-61C593B3-8C97-4D54-A596-8CD0582DAB7DQ49953442-E9585D24-C12C-4413-81D7-31CAA959EBF3Q53113774-3AC428AA-C7AD-48FA-8A64-8860CEDA16B7Q53136887-C40E98E5-4A3A-4562-A8C2-3EF751EB34D5Q54196218-B12FDE16-0D38-4D52-A6BA-BD4C2C901929Q55066009-31D6736C-7F9B-4F4E-9EE3-F2B610B0440C
P2860
Optimizing the use of sunitinib in metastatic renal cell carcinoma: an update from clinical practice.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Optimizing the use of sunitini ...... update from clinical practice.
@en
Optimizing the use of sunitini ...... update from clinical practice.
@nl
type
label
Optimizing the use of sunitini ...... update from clinical practice.
@en
Optimizing the use of sunitini ...... update from clinical practice.
@nl
prefLabel
Optimizing the use of sunitini ...... update from clinical practice.
@en
Optimizing the use of sunitini ...... update from clinical practice.
@nl
P2093
P2860
P1433
P1476
Optimizing the use of sunitini ...... update from clinical practice.
@en
P2093
Alain Ravaud
Cezary Szczylik
Dirk Arnold
John Wagstaff
Manuela Schmidinger
P2860
P304
P356
10.3109/07357901003631080
P577
2010-10-01T00:00:00Z